



THE LATEST INNOVATION IN THE CONTINUUM OF CARE FOR DPN

The WaveWriter Alpha™ Spinal Cord Stimulator (SCS)
is now FDA approved for Diabetic Peripheral Neuropathy (DPN)

37 Americans
live with
diabetes¹
MILLION

50% Will suffer
from DPN²

The American Diabetes Association (ADA) recommends referring DPN patients to a Pain Clinic when pharmacological therapies have no meaningful effect^{3,4}



Topical
Treatment



Pharmacological
Therapies




Interventional
Pain Therapies
(Including SCS)


Due to high risk of addiction and complications, the ADA does not recommend the use of opioids as first or second-line agents for treating DPN patients

REAL-WORLD DPN EVIDENCE⁵

Boston Scientific's real-world RELIEF registry demonstrated high responder rates of $\geq 81\%$ and up to 95% sustained improvement out to 2 years



RESPONDER RATE



SUSTAINED PATIENT
IMPROVEMENT

A PARTNERSHIP FOR PAIN SOLUTIONS

Boston Scientific provides an essential selection of advanced therapies to help patients find relief from chronic pain. In addition, our referral support services can help you connect your patients with pain specialists experienced with Boston Scientific SCS therapy.[§]

Learn about our programs and resources at:



Pain.com/Referral

References:

1. American Diabetes Association. Statistics about diabetes. <https://diabetes.org/about-diabetes/statistics/about-diabetes> Accessed October 8, 2023.
2. Hicks, Selvin. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Current Diabetes Reports*. 2019 Aug 27; 19(10): 86.
3. Pop-Busui R, Ang L, Boulton A, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. *Compendia*. 2022;2022(1):1-32.
4. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care*. 2017;40(1):136-154.
5. Berg R, et al. Global, Multicenter Registry of Prospectively-Enrolled Patients Utilizing SCS for Painful-Diabetic Peripheral Neuropathy (DPN): Long-Term Outcomes. NANS 2024 Annual Meeting.
 - Responder Rate: (n=28 @ 1 year, n=21 @ 2 years, & n=12 @ 3 years, Ongoing study)
 - Sustained Patient Improvement: (n=29 @ 1 year, n=21 @ 2 years, & n=15 @ 3 years, Ongoing study)

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

§The physician locator tool identifies pain management specialists in your area who have met certain qualifying criteria and are experienced with one or more of Boston Scientific pain management therapies. All treatment options should be discussed thoroughly with a pain management specialist.

The Boston Scientific Spinal Cord Stimulator Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, Diabetic Peripheral Neuropathy of the lower extremities, intractable low back pain and leg pain, radicular pain syndrome, radiculopathies resulting in pain secondary to failed back syndrome or herniated disc, epidural fibrosis, degenerative disc disease (herniated disc pain refractory to conservative and surgical interventions), arachnoiditis, multiple back surgeries. The Boston Scientific Spectra WaveWriter™, WaveWriter Alpha™ and WaveWriter Alpha™ Prime SCS Systems are also indicated as an aid in the management of chronic intractable unilateral or bilateral low back and leg pain without prior back surgery. Contraindications, warnings, precautions, side effects. The SCS Systems are contraindicated for patients who: are unable to operate the SCS System, have failed trial stimulation by failing to receive effective pain relief, are poor surgical candidates, or are pregnant.

Refer to the Instructions for Use provided with the SCS System or Pain.com for potential adverse effects, warnings, and precautions prior to using this product.

Warning: Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the diabetic peripheral neuropathy (DPN) population.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

NM-1744207-AB ©2024 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are the property of their respective owners.